Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Novo says oral semaglutide works in diabetic kids

 April 23, 2026

Pharmaphorum

Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.

Clinical DataMetabolic & GLP-1Read full story

Post navigation

Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change →
← BBOT shakes up leadership as RAS competitors get more visibility

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com